Pharmacogenomics is a field dedicated to exploring the contribution of genetics to interindividual variability in drug response. A goal of cardiovascular pharmacogenomics is to guide cardiovascular drug development and selection so as to optimize therapeutic benefit and minimize the potential for toxicity. Genetic-based differences in drug metabolism have long been recognized but just now are on the verge of wider clinical application. Differences in efficacy of cardiovascular drugs (independent of drug concentration) based on common genetic variations (polymorphisms) only recently have begun to be explored, but the potential for clinical application appears promising. Examples are presented of important pharmacodynamic effects of genetic variants on several drugs, including those in antiarrhythmic, reninangiotensin, f-blocker, lipid-lowering, and antithrombotic classes. Principles of pharmacogenomics applied to drug metabolism are discussed that are relevant to drug development and clinical use, and examples are given for CYP450 phase I enzymes, phase II enzymes, and drug transporters. Challenges in establishing true pharmacogenetic associations are discussed, and current and future clinical potential is summarized. Rapid research progress and initial clinical applications with pharmacogenomics are foreseen in the near future.
4. Roses AD. Pharmacogenetics and the practice of medicine. Nature405:857-865, 2000
5.
5. Johnson JA, Humma LM. Pharmacogenetics of cardiovascular drugs. Briefings in Fundamental Genomics and Proteomics1:1-14, 2002
6.
6. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science291:1304-1351, 2001
7.
7. The International Human Genome Mapping Consortium. A physical map of the human genome. Nature409:934-941, 2001
8.
8. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for understanding human biology and medicine. JAMA286:2296-2307, 2001
9.
9. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA287:1680-1689, 2002
10.
10. Vincent GM, Timothy K, Fox J, Zhang L. The inherited long QT syndromes: From ion channel to bedside. Cardiol Rev7:44-55, 1999
11.
11. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res50:224-231, 2001
12.
12. Abbott GW, Sesti F, Splawski I, et al. MiRPI forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell97:175-187, 1999
13.
13. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA97:10613-10618, 2000
14.
14. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol11:691-696, 2000
15.
15. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science297:1333-1336, 2002
16.
16. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation106:1269-1274, 2002
17.
17. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet51:197-205, 1992
18.
18. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised association between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. Lancet355:434-442, 2000
19.
19. Dieguez-Lucena JL, Aranda-Lara P, Ruiz-Galdon M, et al. Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension28:98-103, 1996
20.
20. Exner DV, Dries DL, Donmanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. New Engl J Med344:1351-1357, 2001
21.
21. Schunkert H, Hense HW, Gimenez-Roqueplo AP, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension29:628-633, 1997
22.
22. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens13:1602-1609, 1995
23.
23. Miller JA, Thai K, Sholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int56:2173-2180, 1999
24.
24. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin H type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension28:1081-1084, 1996
25.
25. Mukae S, Aoki S, Itoh S, et al. Bradykinin B2 receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension36:127-131, 2000
26.
26. Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capaicin after cilazapril usage. Respir Med95:130-135, 2001
27.
27. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation103:1644-1648, 2001
28.
28. Roden DM, Brown NJ. Preprescription genotyping: Not yet ready for prime time, but getting there. Circulation103:1608-1610, 2001
29.
29. Liggett SB. Beta-adrenergic receptors in the failing heart: The good, the bad, and the unknown. J Clin Invest107:947-948, 2001
30.
30. Liggett SB. Pharmacogenetic applications of the Human Genome Project. Nature Medicine2001:281-283, 2001
31.
31. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human betal-adrenergic receptor. J Biol Chem274:12670-12674, 1999
32.
32. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem275:23059-23064, 2000
33.
33. Small KM, Wagoner LE, Levin AM, Kardia SLR, Liggett SB. Synergistic polymorphisms of betaland alpha 2c-adrenergic receptors and the risk of congestive heart failure. N Engl J Med347:1135-1142, 2002
34.
34. Humma LM, Puckett BJ, Richardson HE, et al. Effect of betal-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. Am J Cardiol88:1034-1037, 2001
35.
35. S'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the betal-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci99:233-238, 2000
36.
36. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med338:86-93, 1998
37.
37. Carlquist JF, Muhlestein JB, Home BD, Hart NI, Bair TL, Molhuizen HOF, Anderson JL. The cholesterol ester transfer protein Taq lB gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J (in press), 2003
38.
38. Gerdes LU, Gerdes C, Dervinen K, et al. The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. Circulation101:1366-1371, 2000
39.
39. Zambon A, Deeb SS, Brown BG, Hokanson JE, Brunzell JD. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. Circulation103:792-798, 2001
40.
40. Jukema JW, van Boven AJ, Groenemeijer B, et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation94:1913-1918, 1996
41.
41. Marian AJ, Safavi F, Ferlic L, et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol35:89-95, 2000
42.
42. Humphries SE, Luong LA, Talmud PJ, et al. The 5A/6A polymorphism in the promoter of the stromelysin-I gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis139:49-56, 1998
43.
43. de Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol83:852-856, 1999
44.
44. de Maat MP, Kastelein JJ, Jukema JW, et al. -455G/A polymorphism of the betafibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Arterioscler Thromb Vasc Biol18:265-271, 1998
45.
45. Dugi KA, Brandauer K, Schmidt N, et al. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation104:3057-3062, 2001
46.
46. Glorioso N, Manunta P, Filigheddu F, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension37:739-743, 1999
47.
47. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet349:1353-1357, 1997
48.
48. Turner ST, Schwartz GL, Chapman AB, Boerwindle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension37:739-743, 2001
49.
49. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebralvein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med338:1840-1841, 1998
50.
50. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol19:700-703, 1999
51.
51. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP Illa P1(A) polymorphisms display different sensitivities to agonists. Circulation101:1013-1018, 2000
52.
52. Carlsson LE, Santoso S, Baurichter G, et al. Heparininduced thrombocytopenia: New insights into the impact of the FcgammaRlIa-R-H131 polymorphism. Blood92:1526-1531, 1998
53.
53. Risch NJ. Searching for genetic determinants in the new millennium. Nature405:847-856, 2000
54.
54. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol22:1058-1061, 2002
55.
55. loannidis JPA, Ntzani EE, Trikalinos TA, Contopoulosloannidis DG. Replication validity of genetic association studies. Nature Genetics29:306-309, 2001
56.
56. Ardlie KG, Lunmetta KL, Seielstad M. Testing for population subdivision and association in four case-control studies. Am J Hum Genet71:304-311, 2002
57.
57. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science296:2225-2229, 2002
58.
58. Dawson E, Abecasis GR, Bumpstead S, et al. A first-generation linkage disequilibrium map of human chromosome 22. Nature418:544-548, 2002
59.
59. Patil N, Bemo AJ, Hinds DA, et al. Blocks of limited haplotype diversity revealed by high resolution scanning of human chromosome 21. Science294:1719-1723, 2001
60.
60. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA286:2270-2279, 2001
61.
61. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA279:1200-1205, 1998
62.
62. Takanshi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants. Pharmacogenetics10:95-104, 2000
63.
63. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet353:717-719, 1999
64.
64. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation related outcomes during warfarin therapy. JAMA287:1690-1698, 2002
65.
65. Hoffmeyer S, Burk L, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA97:3473-3478, 2000
66.
66. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol16:1250-1255, 1996
67.
67. Anderson JL, Muhlestein JB, Home BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation102:1227-1232, 2000
68.
68. Home BD, Anderson JL, Muhlestein JB, et al. Polymorphisms of the CETP, ABC, MTHFR, LPL, and PAI-I genes predict intermediate endpoints but not angiographic coronary artery disease. J Am Coll Cardiol41:abstract (in press), 2003
